Jian Fang

Peking University — China

Medicine · Health Sciences

35h-index6.2kcitations243works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(132), Lung Cancer Research Studies(63), Colorectal Cancer Treatments and Studies(49), Lung Cancer Diagnosis and Treatment(36), Cancer Immunotherapy and Biomarkers(35)

Publications242 total

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer
European Journal of Cancer·2026
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
The Lancet Oncology·2025· 1 cited
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
European Journal of Cancer·2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
The Lancet Respiratory Medicine·2025· 1 cited
Spatially fractionated radiotherapy combined with CapeOX and bevacizumab for postoperative pulmonary metastasis from urachal carcinoma: a case report
Frontiers in Oncology·2025· 1 citedOpen Access
Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors
Drug Design Development and Therapy·2025Open Access
Multicenter epidemiological investigation and analysis of factors associated with transient synovitis of the hip in 5065 children treated across 32 tertiary children’s hospitals in China
BMC Musculoskeletal Disorders·2025Open Access
Impact of yak excreta on soil bacterial community in alpine marsh under warming conditions
Applied and Environmental Microbiology·2025Open Access
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine·2025· 13 cited
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial
EClinicalMedicine·2025Open Access
P3.12.48 Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy
Journal of Thoracic Oncology·2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Journal of Clinical Oncology·2025· 5 cited
The MiR-21a-5p/transforming growth factor beta/Smad Pathway: A Potential Mechanism Underlying Effects of Qi States on PostMyocardial Infarction Heart Failure and Fibrosis
World Journal of Traditional Chinese Medicine·2025Open Access
Influencing factors of cognitive impairment in patients with thalassemia: a comprehensive review
Hematology·2025Open Access
Metastatic colon adenocarcinoma to the gingiva treated with spatial fractionation radiotherapy: a case report
Frontiers in Oncology·2025· 1 citedOpen Access
Qi deficiency syndrome in heart failure: integrative analysis reveals CISD2-linked lipid metabolic dysregulation and prognostic implications
Traditional Medicine Research·2025Open Access
Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study
Chinese Medical Journal·2025· 1 citedOpen Access
Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors
Cancer Research·2025· 2 cited
Abstract CT009: SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced <i>HER2</i>-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung
Cancer Research·2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Signal Transduction and Targeted Therapy·2025Open Access
page 1 of 13Next →

Frequent Co-authors

Jianying Zhou(19), Ying Cheng(16), Gongyan Chen(14), Jianhua Shi(14), Jiuwei Cui(14), Shun Lü(13), Shundong Cang(12), Xingya Li(12), Nong Yang(11), Jifeng Feng(10), Yueyin Pan(10), Yanqiu Zhao(10), Lin Wu(10), Zhehai Wang(9), Yanping Hu(9), Qiming Wang(8), Lejie Cao(8), Helong Zhang(8), Liyan Jiang(7), Yi Hu(6)